View Older Stories
-
Earnings selloff in this stock has "created attractive setup for 2027": TD Cowen
-
Medtronic, Inc. (MDT) PT Raised to $114 at Needham
-
New PFA survey is most positive for this MedTech stock
-
Medtronic (MDT) Declares $0.72 Quarterly Dividend; 3.1% Yield
-
Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
-
Medtronic (MDT) call put ratio 11.2 calls to 1 put with a focus on 8165 contracts of September 100 calls
-
Piper Sandler Reiterates Neutral Rating on Medtronic, Inc. (MDT)
-
Medical device stocks tumble after HCA flags weak surgical volumes
-
Medtronic, Inc. (MDT) PT Lowered to $100 at TD Cowen
-
Piper Sandler's Spine Doc Survey Results: 'We favor ATEC and GMED as our top picks'
-
Needham Reiterates Buy Rating on Medtronic, Inc. (MDT)
-
Piper Sandler on Medtronic, Inc. (MDT): 'Warming to the Story but Not Quite There'
-
Medtronic, Inc. (MDT) PT Lowered to $85 at UBS, Neutral Rating Maintained
-
TD Cowen Reiterates Buy Rating on Medtronic, Inc. (MDT)
-
Medtronic, Inc. (MDT) PT Lowered to $86 at Truist Securities
-
Medtronic, Inc. (MDT) PT Lowered to $97 at Bernstein SocGen Group
-
Medtronic, Inc. (MDT) PT Lowered to $88 at Jefferies
-
BTIG Upgrades Medtronic, Inc. (MDT) to Buy
-
Medtronic, Inc. (MDT) PT Lowered to $101 at Needham
-
Medtronic files to expand Hugo robotic surgery system to new specialties
-
Medtronic invests in two ICE catheter technology companies
-
Medtronic (MDT) Tops Q4 EPS by 1c, Beats on Revenue; Offers FY27 EPS Guidance
-
Medtronic, Inc. (MDT) PT Lowered to $100 at Mizuho
-
Medtronic earnings preview Q4: softer profit expected with restructuring in focus
-
Medtronic (MDT) call put ratio 1 call to 1 put into quarter results
-
Goldman Sachs Reinstates Medtronic, Inc. (MDT) at Neutral
-
Orchestra BioMed receives $20 million from Medtronic under financing pact
-
Medtronic cyberattack does not affect products or operations
-
Medtronic, Inc. (MDT) PT Lowered to $95 at Jefferies
-
Medtronic, Inc. (MDT) PT Lowered to $90 at UBS to Reflect Cllosing of MiniMed IPO
-
Q1 MedTech quarterly preview: BTIG
-
Medtronic (MDT) Reiterated at Hold by Stifel After Physician Survey
-
Medtronic, Inc. (MDT) PT Lowered to $106 at Evercore ISI
-
Medtronic, Inc. (MDT) PT Lowered to $95 at Stifel
-
Medtronic, Inc. (MDT) PT Lowered to $115 at Argus
-
Piper Sandler on BSX and MDT Following KOL Call
-
Medtronic gets FDA clearance for surgical system in brain, ENT procedures
-
Needham Reiterates Buy Rating on Medtronic, Inc. (MDT)
-
BofA Securities on Medtronic, Inc. (MDT): 'one of few accelerating growth companies in medtech'
-
BofA: We see MDT rev accelerating from new bottom-up model
-
Needham Reiterates Buy Rating on Medtronic, Inc. (MDT)
-
Leerink Partners Reiterates Outperform Rating on Medtronic, Inc. (MDT): acquisition an "incremental positive"
-
Needham Reiterates Buy Rating on Medtronic, Inc. (MDT): "glad to see MDT increasingly pursue tuck-in acquisitions"
-
Truist Securities Reiterates Hold Rating on Medtronic, Inc. (MDT) amid acquisition announcement
-
Piper Sandler's Key Takeaways From CRT 2026
-
Medtronic (MDT) files to offer debt
-
Medtronic receives Japan reimbursement for blood pressure device
-
Medtronic, Inc. (MDT) PT Lowered to $103 at Truist Securities
-
Mizuho Reiterates Outperform Rating on Medtronic, Inc. (MDT)
-
Medtronic, Inc. (MDT) PT Lowered to $120 at Needham

